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Abstract 
Objective: To examine secular trends in demographic, clinical manifestations and 
comorbidity on first presentation of RA prior to DMARD treatment. 
Methods: 2701 patients were recruited over 25years to two UK-based RA inception cohorts: 
the Early RA Study (9 centres; 1986-2001) and the Early RA Network (23 centres; 2002-
2012). Trends in demographic and baseline clinical/laboratory and radiographic variables and 
comorbidities were estimated using mixed effects models, including random effects for 
recruitment centre. 
Results: Age-at-onset increased from 53.2 to 57.7 years in 1990 and 2010 respectively (2.6 
months/year; 95% CI 1.2-4.1). Gender-ratio, the proportion living in deprived areas and 
smoking status were unchanged (p>0.05) and there were no changes in the proportion 
seropositive or erosive at baseline (p>0.05).  After controlling for treatment at the time of 
assessment, ESR reduced and haemoglobin increased over time (p<0.05), however HAQ, 
DAS, DAS28, and joint counts were unchanged (p>0.05). The overall prevalence of 
comorbidity increased from 29.0% in 1990 to 50.7% in 2010, mainly due to cardiovascular 
and non-cardiac vascular conditions including hypertension. There was a significant increase 
in BMI (0.15 units/year; 95% CI 0.11-0.18), resulting in an increase in the prevalence of 
obesity from 13.3% in 1990 to 33.6% in 2010.  
Conclusions: Age-at-onset and comorbidity burden, especially obesity have increased at RA 
presentation over 25 years, reflecting wider demographic trends at the population level. In 
contrast there were no accompanying changes in disease severity assessed by composite 
markers of disease activity, radiographic erosions, seropositivity or HAQ at presentation.  
Treatment strategies in early RA should take greater account of the impact of co-morbidity on 
outcomes.   
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SIGNIFICANCE AND INNOVATIONS 
 Increasing age and level of comorbidity were observed at presentation of rheumatoid 
arthritis (RA) over a 25 year period. 
 In contrast, RA disease severity remained stable over time, prior to disease-modifying 
treatment. 
 Modern management of RA should incorporate a detailed assessment of comorbidities 
in order to better inform treatment stratification. 
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The need to better understand patterns of disease expression in rheumatoid arthritis (RA) and 
also wider patient characteristics is well recognised in modern day rheumatology practice and 
stratified medicine. Several studies report a decreasing severity of RA over time, though 
some controversy remains (1–4)(5).  Reports on long-term outcomes of disease (6–10),  
attribute the reduction in RA severity mainly to the use of earlier and more intensive disease 
modifying treatments (11). These data are compromised by the majority of studies not 
allowing for an assessment of disease severity on first presentation, prior to disease-
modifying anti-rheumatic drug (DMARD) therapy or long term steroids, due to the nature of 
the data collected. As a result, trends at presentation may be confounded by treatment 
commencement prior to the completion of disease severity assessments.  Furthermore, there 
is very little data on the presence of comorbidities in early RA, although these have an 
influence on treatment efficacy and disease outcomes.  An important reason for this is failure 
or variation in the capture of this information.  
Ascertaining the burden of comorbidities in RA is important in clinical practice for several 
reasons, and requires an incorporation of strategies to manage these from the time the patient 
first presents, as well as suppressing the inflammatory burden of RA with traditional 
DMARDs. This is exemplified by the well recognised independent influence of RA on 
adverse cardiovascular outcomes (12). Furthermore, the impact that comorbidities can have 
on DMARD and biologic tolerability and efficacy requires careful treatment selection, to 
optimise outcomes. Thus the treatment strategy selected at first presentation of RA should be 
reflective of the index condition as well as all other co existing factors.  
An increased prevalence of obesity and conditions such as diabetes have been reported in the 
general population (13,14) but, with one exception, not specifically in RA (1). The primary 
objective of this study was therefore to determine whether demographic, clinical 
characteristics and the presence of comorbidities at RA presentation, prior to the initiation of 
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DMARD therapy, have changed over the past 25 years. The study uses data from two 
consecutive UK inception cohorts and hypothesizes that (i) in line with a reduced incidence, 
age at symptom onset would have increased; (ii) due to wider societal trends and increasing 
age at onset, obesity and the presence of comorbidities will have increased; and (iii) based on 
previous literature, and due to better general population health (e.g. greater awareness of the 
effects of smoking) disease severity as indicated by clinical characteristics, inflammatory 
markers and symptoms would have decreased.  
METHODS 
Patient Databases 
The Early RA Study (ERAS) and Early RA Network (ERAN) are multi-centre inception 
cohorts of early RA, which recruited from 9 rheumatology centres in England between 1986-
2001, and 23 centres in England, Wales and Ireland from 2002-2012, respectively, as 
previously described in detail (10). Recruitment figures and median follow up for ERAS and 
ERAN were 1465 and 10 years (maximum 25 years), and 1236 and 6 years (maximum 10 
years) respectively. ERAS and ERAN are consecutive studies with similar design and 
patients recruited within the first 2 and 3 years from symptom onset respectively and prior to 
DMARD therapy in ERAS and the greatest majority of ERAN.   
Clinical, laboratory and radiographic variables 
Standard demographic, clinical and laboratory variables were recorded at the time of patient 
visit (“baseline” visit) and yearly thereafter and strictly prior to DMARD use in ERAS, 
although in ERAN a small proportion of patients were recruited after DMARD initiation 
(indicated on the database).  Variables recorded in both cohorts included gender, age at 
disease-onset, recruitment year, baseline rheumatoid factor and/or anti-CCP, haemoglobin, 
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ESR and Health Assessment Questionnaire disability index (HAQ).(15) Individuals in both 
cohorts were classed as living in a deprived area based on their postal code being ranked in 
the lowest quintile of areas in England by Index of Multiple Deprivation 2007. There were 
some differences in the recording of certain variables relating to disease activity between 
ERAS and ERAN, namely in the recording of the tender and swollen joint count variables 
(TJC, SJC), and patient global assessment (PGA). In ERAS, disease activity was calculated 
based on the original three variable Disease Activity Score (DAS(16,17)), whereas in ERAN 
the four-variable DAS28 ESR method was used(18–20). In line with the change to the 
DAS28 score, joint counts changed from being out of 44 joints to 28 and the focus of PGA 
changed from pain to disease activity, respectively. A formula was used to convert the ERAS 
DAS scores to DAS28 scores (21) to make them comparable across both cohorts, though 
since they are not interchangeable they were examined separately in the two cohorts. Data on 
comorbidities and extra-articular manifestations were recorded at every visit in the medical 
notes and on the case reporting forms, the comorbidities subsequently coded based on the 
ICD-10 coding system. These codes were used to generate a numeric count from which the 
weighted Charlson Comorbidity Index (CCI (21)) was generated. Since RA is the index 
condition for this study it was excluded from the CCI score (modified CCI).   
Treatment profiles  
All centres followed the framework of published UK guidelines for management of RA 
although treatment choice was ultimately left at the discretion of the treating clinician(10). In 
ERAN, a small proportion of patients used synthetic DMARDs prior to recruitment into the 
study. Steroid use in primary care prior to rheumatology review was recorded where 
available. Non-steroidal anti-inflammatory drug (NSAID) use was not recorded and was 
therefore not included in the analysis.  
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Statistical Analysis 
Mixed effects models, accounting for clustering of patients within centres with a random 
effect, were used to estimate the annual change in demographic and clinical variables at first 
presentation to the rheumatologist. The demographic or clinical variable was entered into 
separate models as the outcome and calendar year of onset included as a predictor. Linear 
models were used for continuous variables, and logistic models for binary variables.  All 
analyses were undertaken in Stata 12.1. For variables that were identical across both cohorts 
(e.g. age at onset, sex, ESR), linear trends over time were compared to non-linear trends 
estimated using restricted cubic splines (knots at 1990, 1995, 2000 and 2005), and piecewise 
models with linear trends estimated separately within each cohort. Based on visual inspection 
of the estimated trends and the comparison of model fit using Bayesian Information Criterion 
(BIC), trends over time for all variables were adequately approximated by a linear function. 
Therefore only linear trends are displayed in the results. Note that for logistic models 
estimates of prevalence are curvilinear due to transformation from the logit scale. Standard 
errors for all models were estimated using bootstrap approach with 1000 resamples. Trends in 
baseline demographic variables were adjusted for age, sex, and the time between symptom 
onset and baseline visit. Trends in clinical variables were adjusted for age, sex and use of 
steroids or disease modifying treatment prior to the baseline visit. ESR was log transformed 
for analysis and then back transformed for display.  
RESULTS 
Trends in demographic variables  
Demographic and clinical characteristics by cohort are given in Table 1. The estimated trends 
for variables that were assessed in the same manner across both cohorts are shown in Figure 
1. Age at symptom onset increased from 53.2 years in 1990 to 57.7 years in 2010, an increase 
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of 2.6 months per year (b=0.22 years/year; 95% CI 0.10 to 0.34). The proportion of patients 
that were female, living in a socially deprived area, and were current smokers did not change 
significantly over the 25-year period of recruitment to the two cohorts (p>0.05).  
Figure 1. Trends in demographic variables and clinical characteristics.  
Overall comorbidity burden  
Table 2 shows the overall comorbidity burden by type of comorbidity at baseline across both 
cohorts. The main conditions reported were non-cardiac vascular, mainly hypertension, 
followed by endocrine disease (mainly thyroid problems), cardiovascular (mainly ischaemic 
heart disease) and respiratory diseases (mainly COPD and asthma). Diabetes was reported in 
2.0% (n=54) and osteoporosis in 1.3% at baseline (n=34; 13 in ERAS, 21 in ERAN). 
Psychiatric comorbidity represented 3% of comorbidities at baseline, including depression 
and anxiety (n=68) and less commonly, anorexia and psychosomatic disease (n=13). 
Extra-articular RA disease was present in 12% of patients at baseline and included 
rheumatoid nodules, pulmonary interstitial lung disease (ILD) and secondary Sjogren’s. ILD 
in particular was reported in 0.7% (n=18; 5 in ERAS, 13 in ERAN). 
Trends in comorbidities 
Trends in comorbidities over time are shown in Figure 2 with further information in the 
supplementary material. Presence of a comorbid medical condition increased substantially 
with time, from 29.0% in 1990 to 50.7% in 2010. Relating to a 5% increase in the odds of 
prevalent comorbidity per year later onset, across the observed period (OR=1.05; 95% CI 
1.03 to 1.07). Similar relative increases in the presence of CCI (modified CCI excluding RA) 
(9.6% to 19.8%; OR=1.04; 95% CI 1.02 to 1.07), cardiovascular conditions (1.9% to 6.8%; 
OR=1.07; 95% CI 1.03 to 1.11) and non-cardiac vascular conditions (3.6% to 30.4%; 
OR=1.13; 95% CI 1.10 to 1.16) including hypertension were observed. There was a 
Page 9 of 28
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
Secular changes in comorbidities in RA 
 
9 
 
considerable increase in BMI over time (b=0.15; 95% CI 0.11 to 0.18). This related to an 
increase in the prevalence of obesity from 13.3% in 1990 to 33.6% in 2010 (OR=1.06; 95% 
CI 1.04 to 1.08). The presence of extra-articular conditions (mainly nodules, Raynaud’s and 
Sjogren’s) reduced slightly though non-significantly. Small but non-significant increases 
were observed for diabetes (1990: 1.3%; 2010: 2.5%; OR=1.04; 95% CI 0.99 to 1.08), 
respiratory conditions (1990: 4.5%; 2010: 5.6%; OR=1.01; 95% CI 0.99 to 1.04) and 
gastrointestinal conditions (1990: 2.3%; 2010: 2.7%; OR=1.01; 95% CI 0.97 to 1.05). Trends 
in other conditions including interstitial lung disease and vasculitis are not displayed due to 
low prevalence at baseline. 
Figure 2. Trends in comorbidities over time.  
Trends in disease severity 
Trends in disease severity, adjusting for age at disease-onset, sex, symptom duration and 
treatment prior to the baseline assessment, are shown in Figure 3. (see supplementary 
material for unadjusted trends).  Controlling for age at disease-onset, sex, symptom duration 
and treatment prior to the baseline assessment, there was a reduction in baseline ESR 
(logarithmic scale: b=-0.02; 95% CI -0.02 to -0.01) and an increase in haemoglobin (b=0.04; 
95% CI 0.03 to 0.05). However, controlling for the same variables, HAQ did not change over 
the period of observation (b=0.00; 95% CI -0.01 to 0.01). 
Figure 3. Trends in disease severity. 
Figure 4 displays the estimated trends within each cohort for variables assessed in different 
ways across the two cohorts. DAS28, TJC and SJC were assessed differently in each cohort. 
In ERAS DAS28 converted from the original three variable DAS with 44 joint counts did not 
change significantly over time (DAS28: b=-0.01; 95% CI -0.03 to 0.01; SJC44: b=0.06; 95% 
CI 0.09 to 0.20; TJC44: b=-0.01; 95% CI -0.16 to 0.13). Similarly, in ERAN the DAS28 and 
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swollen and tender joints counts did not change significantly over time (DAS28: b=-0.01; 
95% CI -0.09 to 0.06; SJC28: b=-0.15; 95% CI -0.048 to 0.18; TJC28: b=-0.18; 95% CI -0.50 
to 0.14). 
Figure 4. Trends of variables assessed in different ways across ERAS and ERAN (swollen & 
tender joints recorded out of 44 in ERAS and 28 in ERAN). 
Sensitivity analysis 
Although the trends in disease variables reported above were adjusted for treatment at 
baseline, a further sensitivity analysis was undertaken to examine whether earlier treatment 
explained the lower levels of inflammation. Excluding individuals prescribed steroid or 
DMARDs prior to the baseline assessment, the trends for ESR (logarithmic scale: b=-0.02; 
95% CI -0.03 to -0.02) and Hb (b=0.03, 95% CI -0.02 to -0.04) remained significant.  
DISCUSSION 
This study provides insights into the changing circumstances of the first presentation of RA 
over 25-years, which may have important clinical and health economic implications, for 
example, on the screening and management of comorbid diseases, treatment stratification and 
resource allocation. The detailed analysis of patient and disease characteristics and 
comorbidities at RA presentation, prior to DMARD use and controlling for the small number 
of patients who received steroids prior to study entry, demonstrates: 1) an increasing age at 
symptom onset 2) increasing comorbidity burden 3) reduced inflammatory states and 
unchanged patient symptoms and measures of disease activity. 
The prevalence of comorbid conditions on presentation of RA has significantly increased 
over twenty-five years with rising levels of cardiovascular and non-cardiac vascular 
morbidity (including hypertension) as well as the overall CCI.  Our findings are in line with 
the considerable changes in population demography seen in the UK over time, with a rising 
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prevalence of multimorbidity (22), and obesity (23). The obesity ‘epidemic’ has been a 
highly researched topic across the world, with a recent review supporting increasing levels of 
obesity (24), all of which has wider public health relevance. A possible explanation for this 
change, aside from it representing a true increase in certain comorbidities, is an increased 
awareness of certain conditions over time and better diagnostic and reporting modalities.  
Although non-significant, there was also an increasing trend in endocrine, respiratory and 
gastrointestinal conditions at baseline.  
Whether these observed changes in comorbidity represent a real increase in conditions or are 
alternatively due to improved recognition, the fact is that the recognized burden of 
comorbidity has increased and as such this should impact on modern rheumatology 
management.  The increase in conditions including obesity, hypertension, ischaemic heart 
disease and anxiety/depression at RA presentation make it increasingly important that early 
assessment of new cases includes a broad clinical assessment. Each of these co morbid 
conditions carries a health burden, worthy of treatment and amelioration. Similarly, diabetes, 
osteoporosis and extra-articular ILD, although less common at baseline, are associated with 
significant morbidity and should be screened at baseline.   
Aside from their direct impact on disease outcomes, comorbidities influence the choice of 
pharmacotherapy, for example steroid use in patients with diabetes, osteoporosis and obesity; 
interstitial lung disease and use of methotrexate, leflunomide or TNF inhibitors; 
gastrointestinal disease and use of non-steroidal anti-inflammatory drugs.  Therefore, the 
emphasis at first presentation of RA should not just be on the index disease (RA) but also on 
other co-existing conditions. Treat-to-target strategies are now widely accepted as best 
clinical practice resulting in better outcomes. Emerging evidence, however, demonstrates that 
multimorbidity negatively impacts treatment of RA to target, with lower achievement of 
disease remission in multimorbid patients(22–24)(25)(26). Reasons for this include concerns 
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regarding treatment intensification in the presence of multiple co-existing conditions. Whilst 
treatment-intensification should still remain a priority in poorly controlled disease, it is 
inevitable that in the presence of comorbidity, this will need to be carefully considered and 
tailored to the individual patient.  However, despite existing national and international 
guidelines on the importance of taking into account comorbidities (27) , there is little 
guidance on how to best manage these patients.  
We propose that clinicians in busy clinical settings should screen for comorbidity, at the very 
least for the specific conditions we have identified in this report, based on their frequency, 
potential impact on RA outcome and the availability of relative simple screening tools, with 
care plans in place for rapid referral to other specialists as necessary. The negative influence 
on outcome conferred by a delay in initiating DMARDs, which did not improve over the 
course of the 25-year study period, versus the potential use of suboptimal treatment 
combinations because of the presence of comorbidity is an important issue that clinicians 
should be aware of, with respect to both short and long-term disease outcomes. 
It is interesting that whilst comorbidities are increasing at disease-onset, they are 
accompanied by an unchanged RA severity. The improvement in ESR observed over time 
somewhat contradicts the significant increase in BMI and obesity, as these contribute to a 
higher inflammatory load. However the significant rise in haemoglobin may in part explain 
the fall in ESR.  
The later onset age of RA observed in this study may indicate decreasing RA incidence. This 
is supported by previous studies showing similar trends (20, 21) and suggesting a birth cohort 
effect, that is, a decreasing likelihood of developing RA with successive generations. An 
alternative explanation could be a gradual lowering of the clinical threshold for diagnosing 
RA in older people, pointing towards a period effect rather than a cohort effect. This 
explanation is less likely because our results show a shift in the entire age distribution (with 
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standard deviations remaining unchanged) and the level of clinical variables remains largely 
unchanged.  Another explanation relates to diagnostic criteria but there is no suggestion that 
the proportion of people fulfilling criteria for a diagnosis for RA has changed over time. No 
gender differences were seen over time, similar to other studies (13) and there was no 
significant change in the proportion of people living in socially deprived areas at the time of 
recruitment. 
Evidence based on longitudinal observational studies, including this study, is important and 
provides real-life data as opposed to clinical trial data, which include stringent inclusions and 
exclusion criteria that often exclude patients with multimorbidity. However, this study 
demonstrates that the burden of comorbidity is high and is increasing over time, at the onset 
of disease and prior to DMARD use. Data from other studies including the Norfolk Arthritis 
Register (NOAR), that attempt to account for treatment, add to the ambiguity of the findings 
in this field (4). Extra-articular manifestations of RA were collected routinely in ERAS and 
ERAN, some of which are features of established, poorly controlled disease. Despite small 
numbers at disease onset, there was a trend towards a reduction, but this was non-significant. 
 
The real life setting of the ERAS and ERAN cohorts, the large patient numbers and long 
patient follow-up covering a quarter of a century are important strengths of this study.  
Furthermore, the recruitment of patients within the first 3 years of disease and the availability 
of information on medical treatments, add to the value of the study and enable the 
examination of disease presentation prior to external influences, importantly disease-
modifying treatments.  Limitations of the study include the drop off in numbers of patient 
recruitment as ERAS wound down and ERAN started, which could have introduced some 
bias to the results. However, sensitivity analysis using piecewise models and models allowing 
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for non-linear trends with restricted cubic splines showed no issue with this and trends were 
estimated treating year of onset as a continuous variable to avoid problems with precision.  
Furthermore, assessment of steroid use in primary care may be underestimated and other 
treatment use that may impact on inflammation, particularly NSAIDs but potentially also 
statins was not known. This may partially explain the trends for reduced inflammation.  
A further limitation relates to the self-reported nature of comorbidities, which may have led 
to under estimation of the prevalence. For example, the prevalence of depression was lower 
than expected. We observed a prevalence of 3% for all psychiatric comorbidities which is 
considerably lower than the estimated prevalence of 17% for depressive disorder alone. 
(28)Furthermore, previous research using the ERAS cohort has shown that the prevalence of 
self-reported clinical depression is far lower than expected in comparison to using a screening 
tool. (29) 
In summary, this study demonstrates rising levels of comorbid conditions on first 
presentation of RA, especially obesity, and along with the older age at disease-onset, 
highlights the need for more comprehensive packages of care required at these early stages. 
Our findings support intensification of screening for, and addressing of risk factors for 
comorbidities as part of the overall management of RA in order to improve responses to 
treatment and improved patient outcomes. We also found decreasing levels of inflammation 
on presentation of RA whereas other disease activity features and patient symptoms have 
remained largely unchanged.   
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Table 1. Demographic and clinical characteristics at baseline visit 
Variable Values ERAS (N=1465) ERAN (N=1236) 
Year of onset nmissing, Median (IQR) 0 1992 (3.0) 0 2006 (3.0) 
Age at onset nmissing, Mean (SD) 0 55.3 (14.6) 0 57.0 (14.2) 
Female nmissing, n (%) 0 973 (66.4%) 0 839 (67.9%) 
BMI nmissing, Mean (SD) 199 25.6 (4.5) 117 27.6 (5.3) 
Obese nmissing, n (%) 199 187 (14.8%) 142 303 (27.7%) 
Socially deprived area nmissing, n (%) 83 259 (18.7%) 343 143 (16.0%) 
Smoker nmissing, n (%) 558 199 (21.9%) 19 310 (25.5%) 
Comorbidity nmissing, n (%) 0 431 (29.4%) 0 653 (52.8%) 
Symptoms duration 
(months) 
nmissing, Median (IQR) 0 6 (7.0) 91 6 (9.0) 
HAQ nmissing, Median (IQR) 5 1.0 (1.3) 37 1.0 (1.1) 
ESR (mmHg) nmissing, Median (IQR) 7 37 (3) 183 25 (3) 
Haemoglobin nmissing, Mean (SD) 5 12.6 (1.6) 32 13.1 (1.4) 
DAS nmissing, Mean (SD) 13 5.0 (1.2) 46 4.5 (1.6) 
TJC nmissing, Median (IQR) 5 10 (12.0) 6 5 (9.0) 
SJC nmissing, Median (IQR) 3 15 (19.0) 5 4 (8.0) 
RF and/or Anti-CCP 
positive 
nmissing, n (%) 9 914 (62.8%) 179 639 (60.5%) 
Erosions nmissing, n (%) 32 368 (25.7%) 114 330 (29.4%) 
Steroid prior 
presentation 
nmissing, n (%) 0 0 (0.0%) 0 125 (10.1%) 
DMARD prior 
presentation 
nmissing, n (%) 0 0 (0.0%) 0 168 (13.6%) 
Note. BMI= body mass index; obesity defined as BMI>30; smoker indicates current/previous smoking history; HAQ= Health Assessment 
Questionnaire; ESR= erythrocyte sedimentation rate; TJC = tender joint count (out of 44 in ERAS and 28 in ERAN); SJC = swollen joint count (out 
of 44 in ERAS and 28 in ERAN); PGA = patient global assessment (pain in ERAS and disease activity in ERAN); steroid/DMARD ‘prior’ indicates 
use of these drugs prior to enrolment into the study.  
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Table 2.Comorbidity burden and extra-articular manifestations across ERAS and ERAN on 
presentation  
Type of condition Baseline (n,%) 
COMORBDITIES    
Non-cardiac vascular  
(e.g. hypertension, peripheral vascular disease) 
404, 15 
Endocrine  
(e.g. diabetes, thyroid disease) 
253, 9.4 
Cardiovascular  
(e.g. ischaemic heart disease, congestive cardiac failure) 
173, 6.4 
Respiratory  
(e.g. COPD, asthma) 
141, 5.2 
Osteoarthritis 
(primary or secondary) 
124, 4.6 
Psychiatric 
(e.g. anxiety, depression, psychotic illness, anorexia) 
81, 3.0 
Gastrointestinal 
(e.g. gastritis, inflammatory bowel disease, diverticulitis) 
79, 2.9 
Solid cancer 
(organ-based cancer e.g. lung, prostate) 
79, 2.9 
Dermatological 
(e.g. psoriasis, eczema) 
70, 2.6 
Spinal 
(e.g. disc disease, spinal stenosis) 
51, 1.9 
Cerebrovascular  
(e.g. ischaemic/haemorrhagic stroke) 
40, 1.5 
Neurological 36, 1.3 
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(e.g.  Parkinson’s disease, myasthenia gravis) 
Renal 
(e.g. chronic kidney disease, renal calculi) 
28, 1.0 
Haematological 
(e.g. anaemia) 
24, 0.9 
Ophthalmological 
(e.g. cataract formation) 
25, 0.9 
Gynaecological 
(e.g. non-malignant ovarian or uterine disease) 
16, 0.6 
Hepatic  
(e.g. alcoholic liver disease) 
7, 0.3 
Haematological malignancy 
(e.g. leukaemia, lymphoma) 
4, 0.1 
EXTRA-ARTICULAR MANIFESTATIONS 
All  
(major, e.g. vasculitis, ILD; minor, e.g. nodules, peripheral 
nerve entrapment ) 
323, 12 
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Figure a shows the trends in specific co-morbidities over time 
Figures b & c show the un-adjusted trends in disease severity. 
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